IBM Retirement Fund purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the third quarter, HoldingsChannel reports. The institutional investor purchased 1,416 shares of the medical device company’s stock, valued at approximately $203,000.

Several other large investors have also made changes to their positions in DXCM. Stratos Wealth Partners LTD. bought a new position in shares of DexCom during the third quarter valued at $124,000. Brighton Jones LLC bought a new position in shares of DexCom during the third quarter valued at $204,000. Strs Ohio bought a new position in shares of DexCom during the third quarter valued at $213,000. Bank Pictet & Cie Asia Ltd. bought a new position in shares of DexCom during the second quarter valued at $218,000. Finally, Accredited Investors Inc. bought a new position in shares of DexCom during the second quarter valued at $225,000.

Shares of DXCM opened at $138.15 on Monday. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.71 and a quick ratio of 4.43. The stock has a market capitalization of $12.27 billion, a price-to-earnings ratio of -238.19 and a beta of 0.60. DexCom, Inc. has a 52 week low of $51.04 and a 52 week high of $152.14.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, November 6th. The medical device company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.29. The business had revenue of $266.70 million during the quarter, compared to analysts’ expectations of $242.72 million. DexCom had a negative return on equity of 2.89% and a net margin of 4.72%. The company’s revenue was up 44.5% on a year-over-year basis. As a group, research analysts anticipate that DexCom, Inc. will post -0.19 earnings per share for the current fiscal year.

In related news, EVP Donald Abbey sold 10,550 shares of the stock in a transaction dated Friday, November 9th. The stock was sold at an average price of $149.30, for a total transaction of $1,575,115.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Andrew K. Balo sold 5,000 shares of the stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $145.17, for a total value of $725,850.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 172,700 shares of company stock valued at $24,419,880. Company insiders own 1.80% of the company’s stock.

A number of brokerages have recently issued reports on DXCM. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a report on Saturday, November 10th. Northland Securities upgraded DexCom from an “under perform” rating to a “market perform” rating in a research report on Wednesday, September 12th. Jefferies Financial Group upped their price objective on DexCom to $148.00 and gave the company a “buy” rating in a research report on Wednesday, November 7th. Stephens upped their price objective on DexCom from $170.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, November 7th. Finally, Piper Jaffray Companies upped their price objective on DexCom to $157.00 and gave the company an “overweight” rating in a research report on Wednesday, November 7th. Seven investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $132.50.

TRADEMARK VIOLATION NOTICE: “IBM Retirement Fund Takes Position in DexCom, Inc. (DXCM)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/11/19/ibm-retirement-fund-takes-position-in-dexcom-inc-dxcm.html.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Further Reading: Relative Strength Index

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.